Mindpax engages Plexus Ventures as Exclusive Advisor to Partner its Digital Platform for Severe Mental Illnesses

Oct 18, 2022

Philadelphia and Prague –  Mindpax, the innovative digital therapeutics company focused on improving the lives of people with Severe Mental Illnesses (SMIs), has engaged Plexus Ventures as its contract business development organization to identify partners for further development and commercialization of its monitoring and digital therapeutic solutions targeting bipolar disorder, major depressive disorder and schizophrenia.

The Mindpax system enables patients and treating clinicians to monitor, process and report objective and subjective measurements across major symptom dimensions including mood, sleep, activity, medication and external events. Mindpax then utilizes clinically validated algorithms to provide targeted digital therapy. The solution helps patients and clinicians understand the individual manifestation of the disorder and detects warning signs that could trigger the onset of symptoms, like depression or manic episodes. Mindpax showed clinically significant improvement in stabilization of symptoms, resulting in better quality of life and disability scores.

Over the past five years, Mindpax has collected the largest dataset of its kind in digital psychiatry with more than 350 patients followed for 18+ months in order to assess longitudinal behavioural and actigraphic data in relation to the clinical development of patients with bipolar disorder.

Soňa Sikorova, CEO of Mindpax, said: “The Mindpax team is committed to bringing our innovative solutions to people in need. Plexus is a go-to partner with expertise in digital medicines and partnerships with life science companies, which will be invaluable as we engage in this next step of commercialization. We are excited to expand our business development capabilities with these trusted market leaders.”

Gabriele Tundo, Partner at Plexus Ventures, said: “We embrace Mindpax’s commitment to a rigorous scientific process and development of a clinically validated solution that is meaningful to patients. We are excited to partner with Mindpax and work closely with Soňa and the entire Mindpax team to support them with their mission to empower those struggling with SMIs”.

Plexus Ventures and Mindpax will attend Frontiers Health 2022, 20-21 October in Milan (Italy) and would be available to discuss any interest in partnering Mindpax’s digital solutions for SMIs.

About MINDPAX
MINDPAX is a leading digital therapeutics company tackling Severe Mental Illnesses. We focus on improving the clinical conditions and quality of life of people living with bipolar disorder and other SMIs. To achieve that, Mindpax uses a combination of long-term symptom monitoring and targeted digital therapy. You can learn more about Mindpax at www.mindpax.me.

About PLEXUS VENTURES
PLEXUS VENTURES, founded over 30 years ago, is a leading corporate and business development consultancy for healthcare industry companies. Plexus assists clients of all sizes and capabilities to achieve their strategic business development objectives, advising on M&A, asset divestments and partnership arrangements. Plexus’ industry professionals are conveniently located in the United States, Europe and Asia-Pacific markets, enabling Plexus to benefit its clients with both local knowledge and global reach. To learn more about Plexus Ventures, visit plexusventures.com or connect through LinkedIn.

Trending

News

Plexus Ventures Announces Team Promotions

Philadelphia, Pennsylvania – Plexus Ventures, a prominent corporate and business development boutique for healthcare companies, is pleased to announce two promotions among its team members.Gabriele Tundo, Vice President, has been promoted to Partner. Gabriele joined...

Theresa Covert Walker joins Plexus Ventures as Vice President

Philadelphia, Pennsylvania,  June 11, 2021 – Plexus Ventures is pleased to announce the appointment of Theresa Covert Walker as Vice President based in the Pensacola area.  Theresa joins Plexus after a 27-year career at Merck & Co., bringing significant executive,...